Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers

• Verfasst von: Mordaunt, Charles [VerfasserIn]
• Verfasst von: Weiss, Karl Heinz [VerfasserIn]
• Titel: Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers
• Verf.angabe: Charles E. Mordaunt, Dorothy A. Kieffer, Noreene M. Shibata, Anna Członkowska, Tomasz Litwin, Karl-Heinz Weiss, Yihui Zhu, Christopher L. Bowlus, Souvik Sarkar, Stewart Cooper, Yu-Jui Yvonne Wan, Mohamed R. Ali, Janine M. LaSalle and Valentina Medici
• E-Jahr: 2019
• Jahr: 01 February 2019
• Fussnoten: Gesehen am 28.03.2019
• Titel Quelle: Enthalten in: Epigenetics & chromatin
• Ort Quelle: London : BioMed Central, 2008
• Jahr Quelle: 2019
• Band/Heft Quelle: 12(2019,1) Artikel-Nummer 10,16 Seiten
• ISSN Quelle: 1756-8935
• DOI: doi:10.1186/s13072-019-0255-z
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1662483155

Abstract

Wilson disease (WD) is an autosomal recessive disease caused by mutations in ATP7B encoding a copper transporter. Consequent copper accumulation results in a variable WD clinical phenotype involving hepatic, neurologic, and psychiatric symptoms, without clear genotype-phenotype correlations. The goal of this study was to analyze alterations in DNA methylation at the whole-genome level in liver and blood from patients with WD to investigate epigenomic alterations associated with WD diagnosis and phenotype. We used whole-genome bisulfite sequencing (WGBS) to examine distinct cohorts of WD subjects to determine whether DNA methylation could differentiate patients from healthy subjects and subjects with other liver diseases and distinguish between different WD phenotypes.